Cargando…

Sarcoidosis mortality in Sweden: a population-based cohort study

We aimed to investigate sarcoidosis mortality in a large, population-based cohort, taking into account disease heterogeneity. Individuals with incident sarcoidosis (n=8207) were identified from the Swedish National Patient Register using International Classification of Disease codes (2003‒2013). In...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossides, Marios, Kullberg, Susanna, Askling, Johan, Eklund, Anders, Grunewald, Johan, Arkema, Elizabeth V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886843/
https://www.ncbi.nlm.nih.gov/pubmed/29467203
http://dx.doi.org/10.1183/13993003.01815-2017
_version_ 1783312183795384320
author Rossides, Marios
Kullberg, Susanna
Askling, Johan
Eklund, Anders
Grunewald, Johan
Arkema, Elizabeth V.
author_facet Rossides, Marios
Kullberg, Susanna
Askling, Johan
Eklund, Anders
Grunewald, Johan
Arkema, Elizabeth V.
author_sort Rossides, Marios
collection PubMed
description We aimed to investigate sarcoidosis mortality in a large, population-based cohort, taking into account disease heterogeneity. Individuals with incident sarcoidosis (n=8207) were identified from the Swedish National Patient Register using International Classification of Disease codes (2003‒2013). In a subset, cases receiving treatment ±3 months from diagnosis were identified from the Prescribed Drug Register. Nonsarcoidosis comparators from the general population were matched to cases 10:1 on birth year, sex and county. Individuals were followed for all-cause death in the Cause of Death Register. Adjusted mortality rates, rate differences and hazard ratios (HRs) were estimated, stratifying by age, sex and treatment status. The mortality rate was 11.0 per 1000 person-years in sarcoidosis versus 6.7 in comparators (rate difference 2.7 per 1000 person-years). The HR for death was 1.61 (95% CI 1.47‒1.76), with no large variation by age or sex. For cases not receiving treatment within the first 3 months, the HR was 1.13 (95% CI 0.94‒1.35). The HR was 2.34 (95% CI 1.99‒2.75) for those receiving treatment. Individuals with sarcoidosis are at a higher risk of death compared to the general population. For the majority, the increased risk is small. However, patients whose disease leads to treatment around diagnosis have a two-fold increased risk of death. Future interventions should focus on this vulnerable group.
format Online
Article
Text
id pubmed-5886843
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-58868432018-04-09 Sarcoidosis mortality in Sweden: a population-based cohort study Rossides, Marios Kullberg, Susanna Askling, Johan Eklund, Anders Grunewald, Johan Arkema, Elizabeth V. Eur Respir J Original Articles We aimed to investigate sarcoidosis mortality in a large, population-based cohort, taking into account disease heterogeneity. Individuals with incident sarcoidosis (n=8207) were identified from the Swedish National Patient Register using International Classification of Disease codes (2003‒2013). In a subset, cases receiving treatment ±3 months from diagnosis were identified from the Prescribed Drug Register. Nonsarcoidosis comparators from the general population were matched to cases 10:1 on birth year, sex and county. Individuals were followed for all-cause death in the Cause of Death Register. Adjusted mortality rates, rate differences and hazard ratios (HRs) were estimated, stratifying by age, sex and treatment status. The mortality rate was 11.0 per 1000 person-years in sarcoidosis versus 6.7 in comparators (rate difference 2.7 per 1000 person-years). The HR for death was 1.61 (95% CI 1.47‒1.76), with no large variation by age or sex. For cases not receiving treatment within the first 3 months, the HR was 1.13 (95% CI 0.94‒1.35). The HR was 2.34 (95% CI 1.99‒2.75) for those receiving treatment. Individuals with sarcoidosis are at a higher risk of death compared to the general population. For the majority, the increased risk is small. However, patients whose disease leads to treatment around diagnosis have a two-fold increased risk of death. Future interventions should focus on this vulnerable group. European Respiratory Society 2018-02-22 /pmc/articles/PMC5886843/ /pubmed/29467203 http://dx.doi.org/10.1183/13993003.01815-2017 Text en Copyright ©ERS 2018 http://creativecommons.org/licenses/by/4.0/ This ERJ Open article is open access and distributed under the terms of the Creative Commons Attribution Licence 4.0.
spellingShingle Original Articles
Rossides, Marios
Kullberg, Susanna
Askling, Johan
Eklund, Anders
Grunewald, Johan
Arkema, Elizabeth V.
Sarcoidosis mortality in Sweden: a population-based cohort study
title Sarcoidosis mortality in Sweden: a population-based cohort study
title_full Sarcoidosis mortality in Sweden: a population-based cohort study
title_fullStr Sarcoidosis mortality in Sweden: a population-based cohort study
title_full_unstemmed Sarcoidosis mortality in Sweden: a population-based cohort study
title_short Sarcoidosis mortality in Sweden: a population-based cohort study
title_sort sarcoidosis mortality in sweden: a population-based cohort study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886843/
https://www.ncbi.nlm.nih.gov/pubmed/29467203
http://dx.doi.org/10.1183/13993003.01815-2017
work_keys_str_mv AT rossidesmarios sarcoidosismortalityinswedenapopulationbasedcohortstudy
AT kullbergsusanna sarcoidosismortalityinswedenapopulationbasedcohortstudy
AT asklingjohan sarcoidosismortalityinswedenapopulationbasedcohortstudy
AT eklundanders sarcoidosismortalityinswedenapopulationbasedcohortstudy
AT grunewaldjohan sarcoidosismortalityinswedenapopulationbasedcohortstudy
AT arkemaelizabethv sarcoidosismortalityinswedenapopulationbasedcohortstudy